Ammonium 5-tungsto-2-antimoniate (HPA 23) protected mice partially or completely against two strains of encephalomyocarditis (EMC) virus and one strain of vesicular stomatitis (VSV) virus. The best protective effect was obtained with EMC strain VR I29 and VSV when a single i.p. injection of HPA 23 was administered shortly before virus inoculation. Mice protected by HPA 23 against EMC strain VRI29 had virus titres in the blood and brain similar to those in untreated mice. A synergism between interferon and HPA 23 was observed in mice infected with EMC VR129. Our results demonstrate the in vivo activity of HPA a 3 against two lethal viral infections and suggest that, at least in mice infected with EMC, death may not be related solely to virus multiplication.
INTRODUCTION
Acidification of tungstate or molybdate solutions causes a condensation of tungsten or molybdenum ions with formation of isopolyanions. When foreign ions are present the tungsten or molybdenum ions condense around them and mineral condensed ions (also called heteropolyanions) are formed. We reported in a previous paper that the mineral condensed ion, ammonium 5-tungsto-z-antimoniate (HPA 23) protected mice against murine leukaemia viruses (Jasmin et al. 1974) . The RNA-dependent DNA polymerase of murine oncornaviruses is strongly inhibited by HPA 23 (Chermann, Sinoussi & Jasmin, 1975) . HPA 23 has a wide in vitro antiviral activity against many RNA and DNA non-oncogenic viruses and a rapid evaluation of its antiviral activity has shown that HPA z 3 could protect mice against EMC virus infection (Jasmin et al. 1975) . We report here in vivo studies on two strains of EMC and one strain of VSV.
METHODS
Mice. 4 to 6 weeks old CD-I mice of either sex (purchased from Charles River, Elbeuf, France) were used throughout this study.
Viruses. Strains VRI29 and v77 of EMC virus were obtained from the American Type Culture Collection. Stocks of both strains, VRtZ 9 and v77, were prepared from mouse brain extracts after a single in vivo passage in our laboratory. Virus inoculations (o.z ml) in mice were made subcutaneously (s.c.). The virus preparation of EMC VRI29 titrated by s.c. inoculation contained io75LD50/o.2 ml, whereas the stock of EMC strain v77 contained IOT'°LDs0/o'z ml. One LDs0 in mice (s.c. inoculation) corresponded to 3 and IO TCDs0 in L cell monolayer cultures for VRI29 and v77 strains respectively.
A stock of VSV Indiana serotype, kindly supplied by Dr C. Chany (H6pital SaintVincent-de-Paul, Paris), was prepared in mouse L cells and titrated at IoSLDso/ml in mice by intranasal inoculation. Intranasal inoculation was performed on mice lightly anaesthetized with ether, o. I ml of viral suspension being slowly dropped into the external part of the nose. Only mice which had inhaled the inoculum were included in the experiment, and they were observed for at least IO days.
HPA 23. HPA 23 was prepared according to the method previously described (Jasmin et al. 1974) . It was dissolved in distilled water immediately before use and inoculated i.p. or S.C.
Toxicity of HPA 23 for the mouse. Acute toxicity was determined by a single i.p. injection of graded amounts of HPA 23 into CD-I mice (I o per dose), which were observed for 5 days. Subacute toxicity was determined by injecting graded amounts of the compound into CD-I mice, once a day for 5 consecutive days; animals were observed during the 5 days following the last injection. Acute and subacute LDs0 values for HPA 23 could thus be calculated. While performing the acute toxicity test, it was also possible to determine the lowest dose of HPA 23 which, without killing any of the animals, still caused a significant loss of weight.
Interferon. Mouse interferon was prepared in monolayer cultures of mouse L cells to which ultraviolet-inactivated Newcastle disease virus had been added (Youngner et al. 1966) . The preparations were dialysed overnight at pH 2.o and then for 48 h against 3 changes of cell culture medium.
Statistical analysis. A chi-square test was used for statistical analysis of the percentage of survivors. The Wilcoxon test was used to compare survival times.
RESULTS

Toxicity of HPA 23
Acute toxicity in adult mice was observed with doses of 75o mg]kg of HPA 23. The lowest dose causing a significant weight loss in normal mice was found to be 25o mg/kg i.p. Table 1 summarizes the results of a series of experiments with EMC strain VRI29: a significant protection of the animals was obtained with i.p. or s.c. inoculation of HPA 23 given I h before inoculation of approx. 2o LDs0/mouse of virus. Oral treatment proved ineffective (results not shown).
Effects of HPA 23 on EMC and VSV infections
In view of the results of a number of individual experiments, the data of which are pooled in Table I , a dose of Ioo mg/kg i.p. was chosen as the most effective, although the 5o mg/kg i.p. dose still exhibited a high degree of efficacy when administered before virus inoculation. Subcutaneous inoculations with HPA z3 also proved effective but this route was not investigated further, since it had the disadvantage of being that used for virus inoculation. Comparison with toxicity data of HPA 23 in uninfected mice shows that the most regularly effective dose of the compound against EMC virus mortality, i.e. IOO mg/kg i.p. is 7'5 times below the acute LD~0 of HPA 23 by the same route (75o mg/kg i.p.) and 3"5 times below its subacute toxicity (35o mg]kg i.p.). With a single i.p. injection of IOO mg/kg, a significant protection against EMC was still obtained when the mice received the compound 4 h after virus inoculation but no significant effect was observed when treatment was given 24 h after virus inoculation. NS P < o'o5~ P < o-ot~: Table 2 shows the results of a comparison between the v77 and VRI29 strains of EMC virus with respect to their sensitivity to the protective effect of HPA 23 in mice. In this experiment, mortality in the control animals inoculated with the VRI 29 strain was lower than in the pooled experimental data of Table I but efficacy of HPA 23 treatment was comparable, with a clear dose-effect relationship. In mice inoculated with the v77 strain, on the other hand, the percentage of mice surviving on day 4 after virus inoculation was significantly increased by HPA 23 treatment but even at the Ioo mg/kg i.p. dose, no mice survived on day IO. Thus, while HPA 23 treatment completely protected a highly significant proportion of mice against mortality caused by the VR129 strain (since no animal died of infection beyond the Ioth day following infection), it only prolonged by a few days the average survival time of mice infected with the v77 strain. Table 3 gives the results of a study of the efficacy of HPA 23 treatment in mice inoculated with increasing amounts of the VRI29 strain of EMC virus. Complete protection of a significant number of mice was still obtained when the animals received 2o0 LDs0 of the virus, i.e. IO times more than the usual amount, whereas, with an inoculum of 2oo0 LDs0, only an increased survival time was obtained, as in the case of infection with 2o LDso of the v77 5 VIR 31 (Table 4) ; 30 to 50 ~ of mice treated with HPA 23 were completely protected. The rest of the animals had a prolonged mean survival time compared to control mice.
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Absence of effect of HPA 23 on EMC virus titres in the blood and brain
To determine whether the protection of HPA 23-treated mice against lethal infection by EMC virus strain VRI29 was due to an in vivo inhibition of virus multiplication, 6o mice were each injected with 2o LDs0 of EMC virus, strain VRI29. Half of them had received HPA 23 (IOO mg/kg, i.p.) r h previously; the remainder received distilled water. Groups of 5 treated and control mice were killed at I, 2 and 3 days after infection and pooled brain and blood tissues were titrated in mice or in L cells. The remaining mice were observed for Io days to assess the effect of the drug on their susceptibility to virus. Each method of titration gave essentially similar results, pointing to a moderate viraemia reaching its peak on day 2 and to a steep 4 log~0 increase in virus titre in the brain between day 2 and day 3. No statistically significant differences were found between treated and control mice with respect to blood and brain virus titres at any of the 3 times selected. Thus a high proportion of the treated mice survived although the virus titres in their brains had reached wdues (about IO 7 infectious units/ml) equal to those of the control mice, which died. 
Synergism between HPA 23 and interferon
The virus strain VR ] 29 appears to contain an inhibitor, possibly interferon, since it exhibits a marked prozone effect when titrated in L cells. Because this is the virus strain against which HPA 23 is most effective, it was decided that the combined effect of the drug and interferon should be tested in mice. Results from this experiment are given in Table 5 : synergism was clearly seen in mice that had received 5o mg/kg i.p. or of HPA 23 and 75ooo i.u./mouse interferon i.v. respectively I h and 6 h before s.c. inoculation of too LDs0 of virus.
DISCUSSION
In this report we confirm and extend our earlier observations on the in vivo activity of HPA 23 against lethal viral infections of mice. Treatment of the animals with the drug shortly before or after inoculation of either EMC virus or VSV led to a considerable increase in survival time and to complete protection of a large proportion of the mice.
There is a marked difference, however, between the wide spectrum of in vitro antiviral activity of HPA 23 previously reported and its restricted in vivo activity (Jasmin et al. I975) . Under conditions of treatment similar to those used to demonstrate the activity on infections with EMC virus and VSV, HPA 23 had no effect on the infection of mice with the following mouse-adapted viruses: herpes simplex type z, Semliki Forest and West Nile arboviruses and A2/Ann Arbor/z/62 influenza viruses. A difference in the activity of HPA 23 on two strains of EMC virus was also observed. Such differences in virus strain sensitivity have been described with various antiviral substances such as hydroxybenzyl-benzimidazole (Tamm & Eggers, I963) , SKF 4o49 I, a triazinoindole (Haft et al. 2972) , an adamantane compound (Mathur, Beare & Reed, I973) and a guanidine derivative (Bucknall et al. I973) .
Two findings reported in this study suggest that the in vivo activity of antiviral substances may not always be simply related to a direct inhibition of virus replication: (2) the similarity of virus titres in treated and control mice infected with EMC virus strain I29; (2) a synergism between HPA 23 and interferon. Survival of mice with high titres of virus in the brain has been described by Gresser, Tovey & Bourali-Maury (I975) in mice infected with VSV and treated with interferon. Billiau, Muyembe & de Somer (I972) also reported that in mice infected with influenza virus and treated with chlorite-oxidised oxyamylose, a reduction of the mortality was obtained without significant inhibition of virus multiplication.
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Recently, it has been reported that HPA 23 inhibited in vitro plaque formation by lymphocytic choriomeningitis (LMC) virus and reduced the mortality in the acute infection of the adult mouse by this virus (Streissle, I975). It is interesting to note that no reduction of virus titre was observed in the blood of persistently infected mice. This suggests that, at least with some RNA viruses, death may not be directly related to virus multiplication. It is not known whether the outcome of infection is determined by immunological phenomena or by some other factor(s) sensitive to interferon, HPA 23 or other antiviral substances.
The more pronounced effect of HPA 23 on EMC virus strain VRI29 (which shows a zone phenomenon) compared to strain v77, led us to look for a synergism between interferon and the mineral condensed ion. As shown in Table 5 , this synergism was observed in EMC virus infection. HPA 23 is not an interferon inducer (Jasmin et al. I975) , but it may modify interferon production or action induced by some viruses. The possibility that the more sensitive VRI29 contains interfering defective particles should also be considered. The experiments reported here suggest that the differences observed between in vitro and in vivo systems are far more complicated than the events of virus replication in cell culture. The possibility of immunological involvement merits further study. 
